Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy

被引:0
作者
Ying Wang
Yunjing Zhang
Ping Wang
Xianghui Fu
Weiqiang Lin
机构
[1] Institute of Translational Medicine,Kidney Disease Center, The Fourth Affiliated Hospital
[2] Zhejiang University School of Medicine,Department of Urology
[3] the First Affiliated Hospital,Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy and Cancer Center
[4] Zhejiang University School of Medicine,undefined
[5] West China Hospital,undefined
[6] Sichuan University and Collaborative Innovation Center of Biotherapy,undefined
来源
Molecular Cancer | / 19卷
关键词
CircRNA; Renal cell carcinoma; Biomarker; Targeted therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Renal cell carcinoma (RCC) is the most common malignant kidney tumor and has a high incidence rate. Circular RNAs (circRNAs) are noncoding RNAs with widespread distribution and diverse cellular functions. They are highly stable and have organ- and tissue-specific expression patterns. CircRNAs have essential functions as microRNA sponges, RNA-binding protein- and transcriptional regulators, and protein translation templates. Recent reports have shown that circRNAs are abnormally expressed in RCC and act as important regulators of RCC carcinogenesis and progression. Moreover, circRNAs have emerged as potential biomarkers for RCC diagnosis and prognosis and targets for developing new treatments. However, further studies are needed to better understand the functions of circRNAs in RCC. In this review, we summarize and discuss the recent research progress on RCC-associated circRNAs, with a focus on their potential for RCC diagnosis and targeted therapy.
引用
收藏
相关论文
共 502 条
[1]  
Motzer RJ(1996)Renal-cell carcinoma N Engl J Med 335 865-875
[2]  
Bander NH(2020)Cancer statistics, 2020 CA Cancer Clin 70 7-30
[3]  
Nanus DM(2015)International variations and trends in renal cell carcinoma incidence and mortality Eur Urol 67 519-530
[4]  
Siegel RL(2018)Regional variation of computed tomographic imaging in the United States and the risk of nephrectomy JAMA Intern Med 178 221-227
[5]  
Miller KD(2017)Diagnostic relevance of metastatic renal cell carcinoma in the head and neck: an evaluation of 22 cases in 671 patients Int Braz J rol 43 202-208
[6]  
Jemal A(2019)Cytoreductive nephrectomy in metastatic renal cell Cancer: not all that It's cut out to be JAMA Oncol 5 171-172
[7]  
Znaor A(2016)Kidney cancer: finding a niche for girentuximab in metastatic renal cell carcinoma Nat Rev Urol 13 442-443
[8]  
Lortet-Tieulent J(2016)Renal cell carcinoma: review of etiology, pathophysiology and risk factors Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160 183-194
[9]  
Laversanne M(2011)Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates Eur Urol 59 18-23
[10]  
Jemal A(2017)Treatment of renal cell carcinoma: current status and future directions CA Cancer J Clin 67 507-524